By Fineline Cube 
China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE: NVO) Wegovy (semaglutide 2.4mg), based on primary results from the SELECT study. The study demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes.
SELECT Study Results
The SELECT study, a large-scale clinical trial, showed significant cardiovascular benefits of Wegovy. In adult patients with overweight or obesity and confirmed cardiovascular disease, the drug reduced the risk of MACE, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This approval underscores Wegovy’s role in addressing both weight management and cardiovascular health.
Global Recognition and Health Benefits
Wegovy, the world’s first weekly GLP-1 receptor agonist (GLP-1RA) for long-term weight management, is approved in over 10 countries and regions. The STEP series and SELECT studies, involving approximately 25,000 participants, validated Wegovy’s efficacy in achieving and sustaining weight loss. The drug has shown an average weight loss of about 17%, with one-third of patients experiencing over 20% weight loss lasting at least two years. Additionally, Wegovy offers health benefits beyond weight loss, such as reducing waist circumference, visceral fat, improving blood lipids, and reversing prediabetes.-Fineline Info & Tech